Gregorio Sánchez

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

The Changing Landscape for Stroke Prevention in AF

Menno V. Huisman, Kenneth J. Rothman, Miney Paquette et al. · Journal of the American College of Cardiology · 2017 · 281 citations · Full text

Medicine, Cardiology, Pharmacotherapy +10

May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension

Thomas Beaney, Louise M. Burrell, Rafael R. Castillo et al. · European Heart Journal · 2019 · 268 citations · Full text

Medicine, Health Promotion, Preventive Medicine +17

Social disparities explain differences in hypertension prevalence, detection and control in Colombia

Paul Anthony Camacho, Diego Gómez-Arbeláez, Dora I. Molina et al. · Journal of Hypertension · 2016 · 59 citations · Full text

Medicine, Health Sciences, Population Health Sciences +17